BioNJ's C-Suite Summit: A Meeting of Minds in Life Sciences
BioNJ is thrilled to announce its highly anticipated C-Suite Summit, set for an upcoming Thursday morning at the Bridgewater Marriott. This prestigious event marks the twelfth iteration of the summit, aiming to bring together top-tier executives from various life sciences sectors. These include everyone from ambitious start-ups to well-established corporate giants, covering both public and private enterprises. Participants can expect to engage in meaningful discussions that address the challenges and trends shaping the C-Suite landscape, especially as the industry works to introduce transformative treatments.
Navigating Change in the Biopharmaceutical Sector
The biopharmaceutical industry currently faces unprecedented transformations. With a new wave of innovation emerging, this Summit presents an invaluable platform for industry leaders to both evaluate the current state of life sciences and strategize on how to thrive amidst these changes. "In light of shifting policies and the varied landscape of biopharma investments, we're seeing intense scrutiny on the path forward for our industry," said Debbie Hart, President and CEO of BioNJ. The summit is designed for leaders to engage in fruitful dialogues focused on identifying promising opportunities and collaboratively advancing the industry.
Distinguished Speakers Leading the Conversation
The speaker lineup for the C-Suite Summit features a range of esteemed individuals, including:
- Britt Byers, Sr. Vice President, Human Resources NA, Kyowa Kirin
- Jan Campbell, Managing Partner, Pharmaceuticals & Biotechnology, Korn Ferry
- Donna Conroy, Founder & CEO, SciMar ONE
- Vikki Conway, Sr. Vice President & Head, Human Resources US, Teva Pharmaceuticals
- Kiran Dattani, Customer Success, Transformation, Strategy & Architecture, Google Cloud Healthcare & Life Sciences
- Tom Evegan, Principal, Strategy & Management Consulting, RSM
- Hon. Jim Greenwood, Former Congressman & Former President & CEO, BIO
- Hisham Hamadeh, Ph.D., Sr. Vice President & Global Head, Data Science & AI, Genmab
- John Harlow, Chief Commercial Officer, Melinta Therapeutics
- Debbie Hart, President & CEO, BioNJ
- Paul Hunter, Vice President, Market Access & Commercial Operations, Halozyme
- Garrett Ingram, President & CEO, Cipla Therapeutics
- Christopher Jackson, Managing Member, The Law Office of Christopher S. Jackson
- Haripriya Jain, MS, MBA, Executive Director, Global Value & Access Consulting, Evidera
- Rohan Jain, General Manager, Commercial, Nusano
- Harriet Keane, Partner, McKinsey & Company
- Sydney Klein, Chief Information Security Officer, Bristol Myers Squibb
- Keith Koharski, Executive Director, Global Development IT, Regeneron
- Emer Leahy, Ph.D., President & CEO, PsychoGenics & Chair, BioNJ
- Lisa LeCointe-Cephas, J.D., Partner, DLA Piper
- Will Lewis, J.D., MBA, Chair & CEO, Insmed
- Husseini Manji, M.D., F.R.C.P.C., Professor, Oxford University
- Jake McDowell, Vice President & Head, Market Access, Partner Therapeutics
- Clive Meanwell, M.D., Chairman & Partner, Population Health Partners
- Aamir Mecklai, Managing Director, Healthcare Investment Banking, Bank of America
- Heather Meade, J.D., Principal, EY
- Christopher Mortko, Ph.D., MBA, Vice President, Merck
- Gina Murdoch, MBA, President & CEO, Multiple Sclerosis Association of America
- Brandon Parry, Sr. Partner, McKinsey & Company
- Tarek Rabah, President & CEO, Otsuka Pharmaceuticals
- Deiva Ramachandran, Ph.D., Partner, IBM
- Arda Ural, Ph.D., Partner, EY
- Monika Vnuk, M.D., Sr. Vice President, Global Partnering & Business Development, Sanofi
- Scott White, MBA, Chief Operations Officer, Johnson & Johnson
Agenda Highlights: Delving into Crucial Topics
The C-Suite Summit will explore a range of significant topics vital to the future of the industry, including:
- The Next Wave of Innovation in Life Sciences
- Harnessing Change to Deliver Impactful Innovation
- Policy Uncertainties in an Election Year
- Market Access & Reimbursement
- Topics in Talent: Attraction, Retention & Diversity
- Research & Development in Mental Health
- Continued Evolutions in Go-to-Market Models
- Evolving Capital Markets & Implications for Innovation
- The Digital & AI Era in the Biopharma Industry
BioNJ recognizes the importance of these dialogues. Hart concluded, "From access and regulation to AI, our experts will tackle how the industry can enhance medical innovation and ensure patient access. We are eager for all stakeholders to be part of these crucial discussions."
Frequently Asked Questions
What is the purpose of BioNJ's C-Suite Summit?
The Summit aims to unite business leaders in the life sciences sector to discuss critical innovations and strategies for navigating challenges.
Who are the keynote speakers at the Summit?
The event features prominent leaders from various reputable organizations within the life sciences and biopharmaceutical industries.
What topics will be covered during the event?
Discussions will encompass a range of important issues affecting the sector, including innovation, market access, and the impact of policy changes.
How can I register for the event?
Interested participants may register online with details available on BioNJ's official site.
Is there a fee to attend the C-Suite Summit?
Yes, registration fees are $695 for BioNJ Members and $895 for non-members, indicating the Summit's exclusivity for industry leaders.
